Zacks Research Analysts Lower Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research dropped their Q3 2026 earnings per share (EPS) estimates for Corcept Therapeutics in a research report issued on Wednesday, January 14th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of $0.30 per share for the quarter, down from their previous estimate of $0.32. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.49 EPS, Q1 2027 earnings at $0.48 EPS, Q2 2027 earnings at $0.57 EPS, Q3 2027 earnings at $0.87 EPS, Q4 2027 earnings at $1.29 EPS and FY2027 earnings at $3.21 EPS.

Other research analysts have also recently issued reports about the stock. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Wednesday, December 31st. HC Wainwright lowered their target price on Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Canaccord Genuity Group reduced their price target on Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating on the stock in a research report on Friday, January 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $80.83.

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics stock opened at $34.73 on Friday. The firm has a market capitalization of $3.65 billion, a PE ratio of 39.47 and a beta of 0.23. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 12 month low of $32.99 and a 12 month high of $117.33. The business’s 50-day moving average price is $69.09 and its 200-day moving average price is $72.24.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.02). Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The company had revenue of $207.64 million for the quarter, compared to the consensus estimate of $223.78 million. During the same quarter in the previous year, the firm earned $0.41 earnings per share. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year.

Institutional Trading of Corcept Therapeutics

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after purchasing an additional 1,274,215 shares during the last quarter. Norges Bank bought a new position in shares of Corcept Therapeutics during the 2nd quarter valued at $72,048,000. TD Asset Management Inc boosted its stake in shares of Corcept Therapeutics by 16.6% in the 3rd quarter. TD Asset Management Inc now owns 956,136 shares of the biotechnology company’s stock worth $79,464,000 after buying an additional 136,254 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Corcept Therapeutics by 223.4% in the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after acquiring an additional 587,053 shares during the period. Finally, Epoch Investment Partners Inc. increased its position in Corcept Therapeutics by 10.7% during the third quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock valued at $70,403,000 after acquiring an additional 81,700 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Insider Activity

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the insider directly owned 1,235 shares of the company’s stock, valued at approximately $43,447.30. The trade was a 94.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.53, for a total value of $397,650.00. Following the sale, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. This represents a 32.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 194,500 shares of company stock valued at $14,186,410. Company insiders own 20.80% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised its Q4 2027 EPS estimate for CORT to $1.29 from $1.12, a small upside to that specific quarter despite the firm’s overall bearish stance. Read More.
• Positive Sentiment: Zacks also nudged up its Q4 2026 EPS estimate to $0.49 from $0.43 — another isolated upward revision that could be seen as modestly supportive for near-term quarterly expectations. Read More.
• Neutral Sentiment: Coverage pieces are highlighting Corcept’s profit profile versus peers and discussing growth prospects; these help keep the company on investors’ radar but don’t change fundamentals by themselves. Read More.
• Neutral Sentiment: Industry comparisons (e.g., profitability vs. a faster-growing rival) provide context for valuation debates but are not immediate catalysts. Read More.
• Negative Sentiment: Zacks Research downgraded CORT from “hold” to a “strong sell” and trimmed several near-term and FY2027 EPS forecasts (multiple cuts to Q1–Q3 2026/2027 and a FY2027 cut to $3.21 from $3.35). The downgrade and lower multi-quarter estimates are a clear negative catalyst for sentiment and can pressure the stock. Read More.
• Negative Sentiment: Multiple law firms (Pomerantz, Schall, DJS) have announced investigations alleging potential misstatements or nondisclosures; the emergence of shareholder litigation risk typically weighs on investor sentiment and can create legal and reputational uncertainty. Read More. Read More. Read More.
• Negative Sentiment: An outside price-target cut was reported (a ~28% reduction to $92.82), which can recalibrate upside expectations and contribute to selling pressure from valuation-conscious investors. Read More.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.